The outcomes demonstrated the pivotal role of SUMOylation in orchestrating ERK2 stability, as MG132 treatment effectively shielded ERK2 from degradation in both breast cancer cells (Fig. 5A), suggesting that SUMOylation regulates ERK2 stability via the ubiquitin-proteasome degradation pathway. This evidence concerns the gene MAPK1 and breast cancer.